Market Research Reports and Industry Reports

Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Global Market Watch:

Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019.

Report Focus:

The report Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019 reviews the latest trends in regenerative medicinewith a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments.The study reveals profitable investment strategies for market start-ups,pharmaceutical/biotechnology companies, laboratories,Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyersand many more in preferred locations.

The report primarily focuses on:

Emerging Market Trends
Advancements in the Technological Space
Market Demand of The Segments (By-Region)
Key Growth Areas and Market Size
Region-Wise Demand Factor
Key Competitors Edge
Investment Strategies
Estimates are based on online surveys using customized questionnaires by our research team. Besides information from government databases, company websites, press releases & published research reports are also used for estimates.

The analysis primarily deals by therapeutic area and biological substitutes. Further, the subdivided categories include:

Regenerative MedicineSegmentation
Therapeutic Area
o Orthopedics
o Skin/Integumentary
o Cardiology
o Neurology
o Urology
o Other

Biological Substitutes
o Cells and Biomaterials
o Biomolecules
o Manufacturing Factors and
o Other

The period considered for the regenerative medicinemarket analysis is 2013-2019. The region wise distribution of the market consists of The Americas (USA, Brazil, Canada andRest of The Americas), Europe (Germany, United Kingdom, France, Switzerland, Spain, The Netherlands,Russia and Rest of Europe), Asia-Pacific (Japan, South Korea, Australia, China, India and Rest of Asia-Pacific) and Rest of World (Africa and Middle East).The market growth rate in the major economies such as the U.S., Japan, China etc. are estimated individually.

More than 600 market players are identified in regenerative medicineindustry out of which 21 key companies that project improved market activities in the near future are profiled. The report consists of 99 data charts describing the market shares, sales forecasts and growth prospects. Moreover, key strategic activities in the market including mergers/acquisitions, collaborations/partnerships, product launches/developments are discussed.
I. REPORT FOCUS

I. INTRODUCTION

A. REGENERATIVE MEDICINE IN BRIEF
HISTORY OF ORGAN ENGINEERING

THE METHODOLOGY OF REGENERATIVE MEDICINE
1) HUMAN SUBSTANCES
2) CELLS AND TISSUES
3)EMBRYONIC STEM CELLS
NUCLEAR TRANSPLANTATION
OPPOSITION TO USE OF EMBRYONIC STEM CELLS AND NUCLEAR TRANSPLANTATION

4) NOVEL MATERIALS
THE COMPETENT ASSOCIATION BETWEEN REGENERATIVE MEDICATION AND PHYSICAL THERAPEUTICS
CLINICAL TOOLS AND SYNTHETIC ORGANS
MATERIAL TREATMENTS AND BIO SUBSTANCES
CELLULAR TREATMENTS
PREVALENT HURDLES IN THE PROGRESS OF CELLULAR THERAPIES
BARRIERS
SKELETAL MUSCLE
CARDIAC
BONE
OBJECTIVE MEASURES TOWARD REGENERATIVE REHABILITATION
CONCLUSIONS

B. TISSUE ENGINEERING
REGENERATIVE MEDICINE AND TISSUE ENGINEERING
HISTORY OF TISSUE ENGINEERING
METHODS OF TISSUE ENGINEERING
TISSUE ENGINEERING AND REGENERATIVE MEDICINE IN THE CURRENT MEDICAL ORDER
NIH SPONSORED RESEARCH IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE
INFLUENCING STEM CELLS BY MANIPULATING THEIR ENVIRONMENT
TRANSPLANTING HUMAN LIVERS IN MICE
ENGINEERING MATURE BONE STEM CELLS
USING LATTICES TO HELP ENGINEERED TISSUE SURVIVE
POSSIBLE TREATMENT OPTION FOR WORN OUT/INJURED KNEES
RE-GROWING A NEW KIDNEY

TISSUE ENGINEERING AND BIOMATERIALS
CELL AND TISSUE BANKING STANDARDS AND ACCREDITATION

C. STEM CELLS
INTRODUCTION TO STEM CELLS
HISTORY OF STEM CELLS

TYPES OF STEM CELLS
1) EMBRYONIC STEM (ES) CELLS AND EPIBLAST STEM CELLS
2) NON-EMBRYONIC STEM CELLS (NON-ESC)
TISSUE STEM CELLS
INDUCED PLURIPOTENT STEM (IPS) CELLS

REGENERATIVE MEDICINE AND STEM CELLS
THE MICROENVIRONMENT OF THE STEM CELL
EMBRYONIC STEM CELLS A MORE DETAILED LOOK
BLASTOCYST AS A SOURCE OF STEM CELLS LEGAL ISSUES
NON-EMBRYONIC STEM CELLS
1) AMNIOTIC FLUID DERIVED STEM CELLS
2) CORD BLOOD STEM CELLS
TYPE-1 DIABETES
CARDIOVASCULAR CONDITIONS
CENTRAL NERVOUS SYSTEM

3) BONE-MARROW DERIVED STROMAL STEM CELLS
4) IN-VITRO MSC DIFFERENTIATION
5) STEM CELLS DERIVED FROM FAT TISSUE
6) MONOCYTES

STEM CELL TREATMENTS WHY HAVENT THEY GAINED WIDESPREAD POPULARITY?

APPLICATIONS OF STEM CELLS IN TREATMENT OF VARIOUS DISEASES AND CONDITIONS

A) BONE
I) BONE DEFECTS
II) FRACTURE NON-UNION
III) OSTEOGENESIS IMPERFECTA

B) CARTILAGE

C) CARDIAC MUSCLE

D) URINARY TISSUES BLADDER

E) SPINAL CORD

CONCLUSION

CELL-BASED THERAPIES
CELLS DEVELOPED TODAY ARE FUTURE THERAPIES

D. BIOLOGICAL SUBSTITUTES FOR REGENERATIVE MEDICINE
AREAS IN HUMAN TISSUE CONSTRUCTION
BIOMATERIALS
CELLS
BIOMOLECULES
SAFETY AND PRESENTATION CONCERNS
DEVELOPMENTAL FEATURES
OTHER FACTORS

E. REGENERATIVE MEDICINE AND VARIOUS CONDITIONS
1. SKIN/ INTEGUMENTARY
SKIN-TREATMENT
SKIN REVIVAL
NERVE REVIVAL
SKELETAL MUSCLE REVIVAL

REGENERATIVE DRUGS FOR SKIN DISEASES IPS CELLS TO THE SALVAGE

SKIN AND CUTANEOUS CELLS AND TISSUE APPLICATIONS OPT FOR DEVELOPMENT

DO-US ASSOCIATION IN REGENERATIVE MEDICINE TO SUPPORT ACID ATTACK VICTIMS

2. REGENERATIVE MEDICINES PROGRESS IN ORTHOPEDICS
CONTEMPORARY NOTIONS
APPROACHES
CELLS
MORPHOGENETIC STIMULUS
SCAFFOLDS
MECHANICAL STIMULATION
ADVANCEMENT
BONE

REGENERATIVE MEDICINE IN THE BONE
CARTILAGE
OTHER ORGANS
A. INTERVERTEBRAL DISK
B. MENISCUS
C. LIGAMENT AND TENDON

GENE THERAPY STRATEGY

GENE THERAPY COMMERCIAL MILESTONES
2013
2012
2010

VIEWPOINTS

3. CARDIAC REGENERATIVE MEDICINE
CARDIOVASCULAR AND REGENERATIVE MEDICINE
OUTLINE
TYPE OF CVD

CARDIOVASCULAR DISEASE AND REVIVAL MEDICINE
AASTROM
AMORCYTE
ATHERSYS INC.S
CAPRICOR
CYTOMEDIX
CYTORI THERAPEUTICS
JUVENTAS THERAPEUTICS
MESOBLASTS

4. REGENERATIVE DRUGS FOR NEUROLOGICAL DISABILITIES
REGENERATIVE DRUGS FOR NEUROLOGICAL DISEASES WITH THE USE OF ELECTRICAL STIMULATION
1. INTRODUCTION
2. ELECTRICAL STIMULUS FOR CEREBRAL INFARCTION
3. LONG-TERM POTENTIATION AND NEUROGENESIS
CONCLUSION

5. REGENERATIVE NEPHROLOGY
REGENERATIVE DRUG STRATEGIES TO HEAL NEUROGENIC BLADDER
INTRODUCTION

6. THE ESSENTIALS OF TISSUE ENGINEERING
BIO-SUBSTANCES USED IN GENITOURINARY TISSUE RENOVATION
CELLS FOR UROGENITAL TISSUE REGENERATION TECHNOLOGIES
TISSUE PROGRAMMING STRATEGIES FOR BLADDER BOOST AND REPLACEMENT
BIOSUBSTANCES SCAFFOLDS FOR BLADDER REGENERATION
REGENERATIVE DRUGS FOR BLADDER USING CELL TRANSPLANTATION
CONCLUSION

7. DIABETES AND REGENERATIVE MEDICINE

8. ALZHEIMER'S AND REGENERATIVE MEDICINE

9. AUTOIMMUNE DISORDERS AND REGENERATIVE MEDICINE

10. REGENERATIVE MEDICINE IN OPHTHALMOLOGY - PROSPECT
PREAMBLE
CELLULAR TREATMENTS
RESULTS - ADVANTAGES
LIMITATIONS

BIO-SUBSTANCES IN THE CORNEA
CORNEAL REPLACEMENTS ARE A POSSIBLE OPTION THAT NEEDS TO ADDRESS
BIO-SUBSTANCES NEED TO BE
OVERVIEW OF KPRO

EXERCISE ENGINEERING STRUCTURE TO CORNEAL DISEASE

F. REGENERATIVE MEDICINE THE FUTURE TRENDS
ALTERED DEMOGRAPHICS CREATE GREATER BURDEN OF CHRONIC DISEASE
AN EMERGING INDUSTRY
OBTAINING REGULATORY NORMS IN PLACE
FDA PROCEDURES
CROSS-AGENCY MANAGEMENT
REGULATORY DISCIPLINE

G. GOVERNMENT FUNDING
PUBLIC AND PRIVATE INVESTMENT EXCEEDS $1 BILLION

H. US HEALTHCARE STATISTICS
THE COST IMPACT OF AN AGING POPULATION
POTENTIAL ECONOMIC IMPACT OF REGENERATIVE MEDICINE

II. REGENERATIVE MEDICINE - MARKET BRIEFING
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

II. MARKET ANALYSIS
REGENERATIVE MEDICINE INDUSTRY SNAPSHOT

A. REGENERATIVE MEDICINE - SEGMENTATION

REGENERATIVE MEDICINE GLOBAL
REGENERATIVE MEDICINE - BY GEOGRAPHY
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

REGENERATIVE MEDICINE - BY THERAPEUTIC AREA
REGENERATIVE MEDICINE - THERAPEUTIC AREA - BY GEOGRAPHY
ORTHOPEDICS
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

SKIN/INTEGUMENTARY
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

CARDIOLOGY
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

NEUROLOGY
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

UROLOGY
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE)
THE AMERICAS
EUROPE
ASIA-PACIFIC
REST OF WORLD

REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES - BY TYPE

B. GROWTH RATE ANALYSIS
A. REGENERATIVE MEDICINE MARKET GROWTH RATES BY GEOGRAPHY
B. REGENERATIVE MEDICINE MARKET BY THERAPEUTIC AREA GROWTH RATES

C. INVESTMENT FOCUS

III. INDUSTRY OVERVIEW
A. INDUSTRY ACTIVITIES
MERGERS/ACQUISITIONS/AGREEMENTS/PATENTS GRANTS/JOINT VENTURES/TRENDS, ETC
KITE PHARMA ESTABLISHES MANUFACTURING CAPABILITIES TO SUPPORT DEVELOPMENT AND COMMERCIALIZATION OF CAR AND TCR CANCER IMMUNOTHERAPY PRODUCTS
SIGNIFICANT FINDINGS IN U.S. NATIONAL INSTITUTES OF HEALTHS TRIAL OF PLURISTEMS PLX-R18 CELLS FOR TREATMENT OF ACUTE RADIATION SYNDROME
NOVASEP SELECTED TO COMMERCIALLY BIOMANUFACTURE CELLADONS MYDICAR API
CYTORI BEGINS ENROLLMENT IN ACT-OA: US PHASE II TRIAL FOR KNEE OSTEOARTHRITIS
CAN 3-D PRINTING OF LIVING TISSUE SPEED UP DRUG DEVELOPMENT?
TEAM CREATES NEW APPROACH TO GENE THERAPY
CELLULAR DYNAMICS' ICELL HEPATOCYTES ENABLE MALARIA-IN-A-DISH STUDIES
CESCA THERAPEUTICS ANNOUNCES APPROVAL OF ITS MARROWXPRESSTM SYSTEM IN INDIA
VOYAGER THERAPEUTICS & GENZYME ANNOUNCE MAJOR STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL AAV GENE THERAPIES FOR PATIENTS WITH CNS DISORDERS
VALEANT PHARMACEUTICALS ANNOUNCES EXPIRATION OF BID DEADLINE IN CONNECTION WITH AGREEMENT TO ACQUIRE ASSETS FROM DENDREON
3-D PRINTERS TAKE CENTER STAGE IN JAPANS REGENERATIVE MEDICINE
CYNATA PARTNERS WITH UWA CENTRE FOR CELL THERAPY AND REGENERATIVE MEDICINE
ASTRAZENECA ANNOUNCES COLLABORATIONS TO USE CRISPR TECHNOLOGY FOR GENOME EDITING ACROSS ITS DRUG DISCOVERY PLATFORM
AVITA MEDICAL ANNOUNCES FIRST PATIENT ENROLMENT IN US PIVOTAL STUDY OF RECELL
USING 3D PRINTING, MAKERBOT AND FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH CREATE CARTILAGE TO REPAIR TRACHEAL DAMAGE
SISTEMIC AND ROSLIN CELLS ANNOUNCE GROUND-BREAKING COLLABORATION AGREEMENT ON IPSC CHARACTERISATION AS PART OF MAJOR EUROPEAN INNOVATIVE MEDICINES INITIATIVE PROGRAMME
ATHERSYS AND CELL THERAPY CATAPULT ANNOUNCE GRANT TO SUPPORT CLINICAL DEVELOPMENT OF STEM CELL THERAPY FOR SEVERE ACUTE RESPIRATORY CONDITION
CELL THERAPY CATAPULT AND TRAKCEL TO COLLABORATE ON RESEARCH PROJECT
NEOSTEM AND INVETECH ANNOUNCE AGREEMENT TO DEVELOP CLOSED PROCESSING SYSTEM FOR CELL THERAPY MANUFACTURING
NUO THERAPEUTICS AND ROHTO PHARMACEUTICAL CO. SIGN EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT FOR AURIX IN JAPAN
RESEARCHERS GROW FUNCTIONAL TISSUE-ENGINEERED INTESTINE FROM HUMAN CELLS
HART AND MAYO CLINIC COLLABORATE ON REGENERATED TRACHEA, ESOPHAGUS AND HEART VALVE
NOVARTIS COLLABORATES WITH INTELLIA THERAPEUTICS AND CARIBOU BIOSCIENCES TO EXPLORE MAKING MEDICINES AND DRUG DISCOVERY TOOLS WITH CRISPR GENOME EDITING TECHNOLOGY
TXCELL AND FERRING COLLABORATION WITH LEAD PRODUCT OVASAVE
ORTHOCELL AND BONESUPPORT ENTER INTO BONE REPAIR PARTNERSHIP
INVIVO THERAPEUTICS ANNOUNCES FDA APPROVAL TO EXPEDITE ENROLLMENT FOR ONGOING PILOT TRIAL
BIOTIME, INC. SUBSIDIARY ONCOCYTE CORPORATION COMPLETES INITIAL ENROLLMENT OF CLINICAL STUDY OF URINE-BASED BLADDER CANCER DIAGNOSTIC
HERAEUS MEDICAL LICENSES PLATFORM POLYMER TECHNOLOGY TO FURTHER ITS REGENERATIVE ORTHOPEDICS STRATEGY
VOYAGER THERAPEUTICS AND MASSBIOLOGICS ANNOUNCE STRATEGIC COLLABORATION FOR VIRAL VECTOR MANUFACTURING
NYSCF AND THE CMTA ENTER COLLABORATION TO ADVANCE NEUROPATHIES RESEARCH
LEADING BONE REPAIR COMPANY BONESUPPORT AND REGENERATIVE MEDICINE COMPANY ORTHOCELL LTD ANNOUNCE A HEADS OF AGREEMENT
PFIZER EXPANDS RARE DISEASE RESEARCH WITH ESTABLISHMENT OF GENE THERAPY PLATFORM
ESTABLISHMENT OF GENE THERAPY RESEARCH IN PFIZER RARE DISEASE
GE HEALTHCARE LIFE SCIENCES LICENSES CRISPR GENE ENGINEERING TECHNOLOGY PATENTS FROM BROAD INSTITUTE
ORGANOVO COLLABORATES WITH YALE TEAM TO DEVELOP 3-D ORGAN TISSUES FOR SURGICAL TRANSPLANTATION RESEARCH
PLURISTEM GRANTED PATENT IN SINGAPORE FOR ITS 3D CELL EXPANSION TECHNOLOGY
STEM CELL AGENCY & ISRAEL ANNOUNCE INTERNATIONAL COLLABORATION TO ADVANCE STEM CELL RESEARCH
HARVARD APPARATUS REGENERATIVE TECHNOLOGY NO LONGER SUPPORTING STUDIES IN RUSSIA; WILL CONTINUE FOCUS ON PRECLINICAL PROCESSES IN THE U.S. AND EU
JAPANESE LEGISLATION TAKES EFFECT FOR EXPEDITED APPROVALS OF REGENERATIVE MEDICAL PRODUCTS
AASTROM BIOSCIENCES CHANGES NAME TO VERICEL CORPORATION
JUNO T CELL THERAPY FOR LEUKEMIA GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION
OCATA THERAPEUTICS RECEIVES ADVANCED THERAPY MEDICINAL PRODUCT DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY
TRANSPOSAGEN BIOPHARMACEUTICALS ENTERS INTO RESEARCH COLLABORATION AND WORLDWIDE LICENSE AGREEMENT WITH JANSSEN FOR ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES
POLAND AND CALIFORNIA ANNOUNCE INTERNATIONAL COLLABORATION TO ADVANCE STEM CELL RESEARCH TOWARD CURES
ADVANCED CELL TECHNOLOGY CHANGES NAME TO OCATA THERAPEUTICS
CYTOMEDIX ANNOUNCES CORPORATE NAME CHANGE TO NUO THERAPEUTICS, INC.
CARDIO3 BIOSCIENCES ACQUIRES CORQUEST MEDICAL INC.
UNIVERSITY AND GSK COLLABORATION AIMS TO TACKLE MYELIN REGENERATION
THE NEW YORK STEM CELL FOUNDATION RESEARCH INSTITUTE ANNOUNCES LARGEST-EVER STEM CELL REPOSITORY
TERUMO BCT AND ONEBLOOD PARTNER IN A TREATMENT USE PROGRAM OF AN INVESTIGATIONAL DEVICE TO HELP IMPROVE BLOOD SUPPLY SAFETY
ROOSTERBIO SELECTS BIOLIFE SOLUTIONS CRYOSTOR TO COMMERCIALIZE HUMAN BONE MARROW-DERIVED STEM CELLS
PLURISTEM ADVANCES ITS SECOND MAJOR CELL THERAPY PRODUCT LINE FROM DEVELOPMENT TO LARGE-SCALE MANUFACTURING
CYTORI PATENTS AUTOMATED TISSUE PROCESSING DEVICE IN JAPAN AND TREATMENTS FOR WOUND HEALING IN CHINA
OSIRIS AND ARTHREX ANNOUNCE AN EXCLUSIVE PARTNERSHIP FOR THE COMMERCIALIZATION AND DEVELOPMENT OF CARTIFORM
THERMO FISHER SCIENTIFIC ANNOUNCES ITS ION PGM DX NEXT GENERATION SEQUENCING SYSTEM IS NOW CE-MARKED FOR IN VITRO DIAGNOSTIC (IVD) USE
ACT ANNOUNCES POSITIVE RESULTS FROM TWO CLINICAL TRIALS PUBLISHED IN THE LANCET USING DIFFERENTIATED STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM (RPE) CELLS FOR THE TREATMENT OF MACULAR DEGENERATION
PROMETHERA BIOSCIENCES RECEIVES APPROVAL IN BELGIUM TO ENROLL PATIENTS IN THE IMMINENT HEP002 PHASE IIB/III CLINICAL TRIAL
THE NATIONAL STEM CELL FOUNDATION PARTNERS WITH THE ORTHOPAEDIC RESEARCH AND EDUCATION FOUNDATION ON STEM CELL RESEARCH FOR THE REGENERATION AND REPAIR OF MUSCULOSKELETAL TISSUES
CARDIO3 BIOSCIENCES RECEIVES AUTHORIZATION TO ENROLL PATIENTS IN SWITZERLAND IN ITS PHASE III CLINICAL TRIAL CHART-1
SMITH & NEPHEW ANNOUNCES TOP-LINE RESULTS OF HP802-247 PHASE 3 STUDY
NEOSTEM RANKED AS ONE OF THE FASTEST GROWING COMPANIES IN NEW YORK CITY
CESCA THERAPEUTICS ANNOUNCES AGREEMENT WITH NEW YORK UPSTATE CORD BLOOD BANK
OXFORD BIOMEDICA ACQUIRES WINDRUSH COURT OFFICE AND LABORATORY FACILITIES
ASTELLAS ANNOUNCES RESEARCH COLLABORATION WITH HARVARD MEDICAL SCHOOL INVESTIGATOR FOR TREATMENT OF RETINAL DEGENERATION
OXFORD BIOMEDICA ANNOUNCES NEW PROCESS DEVELOPMENT AND MANUFACTURING COLLABORATION WHICH INCLUDES LENTIVECTOR LICENCE AGREEMENT
BONE THERAPEUTICS EXTENDS ALLOB PHASE I/IIA TRIAL TO GERMANY
BRAINSTORM GETS FDA FAST-TRACK STATUS FOR ALS STEM CELL THERAPY
TC BIOPHARM AND SISTEMIC ANNOUNCE COLLABORATION TO DEVELOP AN INNOVATIVE RANGE OF CANCER-SPECIFIC THERANOSTIC PRODUCTS
HISTOGENICS AND INTREXON ANNOUNCE FORMATION OF EXCLUSIVE CHANNEL COLLABORATION FOR CARTILAGE REPAIR THERAPIES
RESEARCHERS DEVELOP NOVEL GENE/CELL THERAPY APPROACH FOR LUNG DISEASE
MESOBLAST PARTNER JCR PHARMACEUTICALS FILES FORMARKETING APPROVAL OF THE FIRST ALLOGENEIC STEM CELL PRODUCT IN JAPAN
CESCA THERAPEUTICS ANNOUNCES APPROVAL OF ITS AXP(R) AUTOXPRESS(R) SYSTEM IN TAIWAN
HORIZON DISCOVERY GROUP PLC ACQUIRES SAGE LABS INC
BAXTER TO FORM NEW GLOBAL INNOVATION AND R&D CENTER NEAR BOSTON FOR ITS BIOPHARMACEUTICALS BUSINESS
ADVANCED CELL TECHNOLOGY ANNOUNCES FINAL PATIENT TREATED IN STARGARDTS MACULAR DEGENERATION PHASE 1 TRIAL IN THE UNITED KINGDOM
FIBROCELL SCIENCE AND INTREXON ADVANCE GM-HDF-COL7 TOWARD CLINICAL DEVELOPMENT FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
GENZYME COLLABORATES ON GENE THERAPY FOR RARE DISEASE THAT CAUSES CHILDHOOD BLINDNESS
STUDY DETERMINES MIMEDX ALLOGRAFT EFFECTIVELY RECRUITS CIRCULATING STEM AND PROGENITOR CELLS
BIOLIFE SOLUTIONS AND SAVSU TECHNOLOGIES ANNOUNCE EXCLUSIVE DISTRIBUTION AGREEMENT
UTSW RESEARCHERS WORKING TO REGENERATE HEART, NERVE CELLS
MAYO CLINIC CENTER FOR REGENERATIVE MEDICINE FORMS COLLABORATION WITH NATIONAL UNIVERSITY IRELAND GALWAY
ACCUREXA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH UC SAN FRANCISCO
MEDPACE CONTINUES TO EXPAND THERAPEUTIC LEADERSHIP IN ONCOLOGY DRUG DEVELOPMENT
REGENERATIVE MEDICINE TO BE INSURED
MIMEDX SIGNS DISTRIBUTION AGREEMENT WITH ZIMMER
CANCER RESEARCH UK, CANCER RESEARCH TECHNOLOGY AND ASTERIAS BIOTHERAPEUTICS PARTNER TO TRIAL IMMUNOTHERAPY VACCINE FOR LUNG CANCER
MABVAX THERAPEUTICS ENTERS AGREEMENTS WITH MEMORIAL SLOAN KETTERING CANCER CENTER AND JUNO THERAPEUTICS FOR DEVELOPMENT OF ANTI-CANCER THERAPEUTICS
SANGAMO BIOSCIENCES ANNOUNCES TARGET DATE FOR FIRST IND FOR SANGAMOS IN VIVO ZFN GENOME-EDITING PLATFORM FOR MONOGENIC DISEASES
STEM CELL AGENCY INVESTS $16 MILLION TO FIGHT DIABETES AND ANNOUNCES PLAN TO LAUNCH CIRM 2.0
HARVARD APPARATUS REGENERATIVE TECHNOLOGY OBTAINS ORPHAN DRUG DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR HART-TRACHEA
SCIENTISTS FIND WAY TO EXPAND BLOOD STEM CELL PRODUCTION IN LAB
ABBVIE AND CALICO ANNOUNCE A NOVEL COLLABORATION TO ACCELERATE THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NEW THERAPIES
ARTIFICIAL VIRUS PROMISES EFFECTIVE DRUG DELIVERY AND GENE THERAPY
CELLULAR BIOMEDICINE GROUP LAUNCHES CLINICAL RESEARCH STUDY FOR CARTILAGE DEFECT STEM CELL THERAPY
BONE THERAPEUTICS SUPPORTS PIONEERING RESEARCH BY BACKING PROJECTS VITAL TO REGENERATIVE MEDICINE RESEARCH
REGENEUS'S HIQCELL OBTAINS APPROVAL FROM AFL
BIOTIME TO COLLABORATE WITH THE UNIVERSITY OF WISCONSIN AND LOUVAIN UNIVERSITY IN TEST OF HYSTEM-BASED HYDROGEL FOR VOCAL FOLD SCARRING
PAVING THE WAY FOR GENE THERAPY IN HUNTINGTON'S DISEASE
ASTERIAS BIOTHERAPEUTICS RECEIVES U.S. FDA CLEARANCE TO INITIATE PHASE 1/2A CLINICAL TRIAL OF AST-OPC1 IN PATIENTS WITH CERVICAL COMPLETE SPINAL CORD INJURY
CESCA THERAPEUTICS ADVOCATES BENEFITS OF CELL THERAPY TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES
MESOBLAST UNVEILS PATH TO BRING ITS KEY PRODUCTS TO MARKET
REGENEUS ENTERS PARTNERSHIP WITH CRYOSITE FOR NEW STEM CELL PRODUCTS
BIOLIFE SOLUTIONS CRYOSTOR AND HYPOTHERMOSOL NOW EMBEDDED IN 130 REGENERATIVE MEDICINE CLINICAL TRIALS
VIACYTE, INC. ANNOUNCES SIGNING OF RIGHTS AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT LLC.
CYTOMEDIX PARTNERS WITH NET HEALTH TO EXPAND CED DATA COLLECTION CAPABILITIES TO APPROXIMATELY 400 ADDITIONAL WOUND CARE CENTERS
NOVARTIS TO INVEST IN ISRAEL'S GAMIDA CELL, COULD BUY OUT COMPANY
BARDA EXECUTES CONTRACT OPTION WITH CYTORI FOR CONTINUED DEVELOPMENT OF THERMAL BURN INJURY COUNTER MEASURE
VIACYTE, INC. ANNOUNCES FDA ACCEPTANCE OF IND TO COMMENCE CLINICAL TRIAL OF VC-01 CANDIDATE CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES
FDA CLEARS MAYO CLINIC FOR MANUFACTURE OF NUROWN AND PARTICIPATION IN BRAINSTORMS PHASE 2 ALS TRIAL
ENGINEERING NEW BONE GROWTH
THE ALLIANCE FOR REGENERATIVE MEDICINE AND THE ALLIANCE FOR ADVANCED THERAPIES MERGE
TISSUE DEVELOPMENT 'ROADMAP' CREATED TO GUIDE STEM CELL MEDICINE
ORGANOVO TO OFFER PRECLINICAL DRUG TESTS BASED ON 3-D LIVER TISSUE
CEDARS-SINAI HEART INSTITUTE OPENS FIRST-OF-ITS-KIND RESEARCH STEM CELL CLINIC FOR CARDIAC PATIENTS
3-D BIOENGINEERED BRAIN TISSUE GROWN IN LAB
STEM CELL THERAPY: FDA REGULATORY SCIENCE AIMS TO FACILITATE DEVELOPMENT OF SAFE AND EFFECTIVE REGENERATIVE MEDICINE PRODUCTS
UNIQURE ACQUIRES CARDIOLOGY GENE THERAPY COMPANY INOCARD
HUMAN LONGEVITY, INC. AND CELGENE CELLULAR THERAPEUTICS SIGN LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE PLACENTAL STEM CELL POPULATION, PSC-100 FOR MULTIPLE THERAPEUTIC APPLICATIONS
VIVEX BIOMEDICAL AND AKRON BIOTECH: COLLABORATIVE VENTURE IN REGENERATIVE MEDICINE
JAPAN'S REPROCELL ANNOUNCES ACQUISITION OF TWO STEM CELL COMPANIES
CHIESI AND UNIQURE PROVIDE UPDATE ON GLYBERA LAUNCH
BIOLIFE SOLUTIONS CRYOSTOR DEMONSTRATES SUPERIOR CELL PRESERVATION IN MULTICENTER BIOBANKING STUDY
CELLULAR BIOMEDICINE GROUP ANNOUNCES ACQUISITION OF IMMUNE CELL THERAPY TECHNOLOGY AND U.S. PATENT
BIOLIFE SOLUTIONS CRYOSTOR DEMONSTRATES SUPERIOR CELL PRESERVATION IN MULTICENTER BIOBANKING STUDY
LIGHT-INDUCED NANOCARRIERS SWITCH ON IMPROVED GENE THERAPY
ORTHOCELL DELIVERS EXCELLENT RESULTS IN TENNIS ELBOW TRIAL
MESOBLAST MPCS TRIAL TO TEST FOR END-STAGE HEART FAILURE
BIOTIME, INC. SUBSIDIARY ONCOCYTE CORPORATION EXPANDS CLINICAL DEVELOPMENT OF BLADDER CANCER DIAGNOSTIC BY INITIATING A LARGE MULTI-SITE CLINICAL TRIAL
CARNEGIE MELLON CHEMISTS CREATE NANOFIBERS USING UNPRECEDENTED NEW METHOD
CELLECTIS SELLS ITS SWEDISH SUBSIDIARY, CELLECTIS AB, TO THE JAPANESE COMPANY TAKARA BIO INC.
WYSS INSTITUTE LAUNCHES ORGANS-ON-CHIPS-FOCUSED STARTUP
STEM CELL ADVANCE MAY INCREASE EFFICIENCY OF TISSUE REGENERATION
LION BIOTECHNOLOGIES ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH MOFFITT CANCER CENTER
WHITEHEAD INSTITUTE RESEARCHERS CREATE NAVE PLURIPOTENT HUMAN EMBRYONIC STEM CELLS
3-D PRINTED TISSUES ADVANCE STEM CELL RESEARCH
ZIOPHARM ANNOUNCES EXPANSION OF GROUND-BREAKING SYNTHETIC IMMUNO-ONCOLOGY PROGRAMS WITH INTREXON AND CLINICAL PROGRAM UPDATE
LILLY AND IMMUNOCORE ENTER IMMUNOTHERAPY AGREEMENT TO CO-DISCOVER AND CO-DEVELOP NOVEL CANCER THERAPIES
TRANSPLANTING GENE INTO INJURED HEARTS CREATES BIOLOGICAL PACEMAKERS
STEM CELL THERAPY IN CARDIOVASCULAR DISEASE: PAST OBSTACLES AND PROMISING NEW DIRECTIONS
MICROBIOLOGICS LICENSES BIOMATRICA TECHNOLOGY FOR MOLECULAR CONTROLS
REGENEUS SECURES EXCLUSIVE WORLDWIDE RIGHTS FOR NEW THERAPEUTIC HUMAN CANCER VACCINE
UNIVERSITY OF PENNSYLVANIA'S PERSONALIZED CELLULAR THERAPY FOR LEUKEMIA RECEIVES FDA'S BREAKTHROUGH THERAPY DESIGNATION
RESEARCHERS REGROW HUMAN CORNEAS: FIRST KNOWN TISSUE GROWN FROM A HUMAN STEM CELL
STEM CELLS: HOPE ON THE LINE
IMPROVING STEM CELLS' REGENERATIVE POTENTIAL
ETHICS OF BIOENGINEERING ORGANS AND TISSUES
MESOBLAST MPCS SHOW ENCOURAGING RESULTS IN TREATING HEART FAILURE
BLUEBIRD BIO ACQUIRES PRECISION GENOME ENGINEERING, A PRIVATELY HELD GENE-EDITING COMPANY
REGENEUS ENTERS INTO US MARKETING TRIAL AGREEMENT FOR NOVEL CANINE CANCER VACCINE
AGTC AND SAFC CREATE STRATEGIC PARTNERSHIP TO PROVIDE GENE THERAPY MANUFACTURING SERVICES
DIMENSION THERAPEUTICS AND BAYER HEALTHCARE ENTER COLLABORATION TO DEVELOP NOVEL GENE THERAPY FOR HEMOPHILIA A
UT SOUTHWESTERN RESEARCHERS DISCOVER BIOMARKER FOR MESENCHYMAL STROMAL CELL FUNCTION IN HUMAN BODY
PFIZER AND CELLECTIS ENTER INTO GLOBAL STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION
FIBROCELL SCIENCE ANNOUNCES EXCLUSIVE TECHNOLOGY LICENSE AGREEMENTS WITH UCLA TO ADVANCE THE DEVELOPMENT OF PERSONALIZED CELL THERAPIES
AASTROM ANNOUNCES STRATEGIC PLAN FOR RECENTLY ACQUIRED CELL THERAPY AND REGENERATIVE MEDICINE BUSINESS
CCRM AND STEM CELLS AUSTRALIA AGREE TO COLLABORATE IN THE GLOBAL TRANSLATION OF STEM CELL RESEARCH
CARDIO3 BIOSCIENCES TEAMS UP WITH MEDISUN INTERNATIONAL TO CREATE CARDIO3 BIOSCIENCES ASIA HOLDINGS LTD, A JOINT VENTURE AIMED AT CONDUCTING PIVOTAL CLINICAL PROGRAMS IN GREATER CHINA
TXCELL GRANTED CERTIFICATE OF GMP COMPLIANCE FROM ANSM FOR CELL THERAPY MANUFACTURING FACILITY
UCLB SIGNS EXCLUSIVE LICENCING AGREEMENT WITH COLLAGEN SOLUTIONS FOR NEXT GENERATION COLLAGEN PRODUCTS
CELLECTIS ENTERS INTO AN AGREEMENT WITH CELLFORCURE FOR THE CGMP MANUFACTURING OF ALLOGENEIC CART CELLS
ADAPTIMMUNE ENTERS STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION WITH GLAXOSMITHKLINE TO DEVELOP AND COMMERCIALISE NOVEL CELL-BASED THERAPIES
AASTROM COMPLETES ACQUISITION OF SANOFI'S CELL THERAPY AND REGENERATIVE MEDICINE BUSINESS
PHARMACELL TO FINALIZE PURCHASE OF CELL THERAPY PRODUCTION FACILITY
MESOBLAST'S MPCS ENHANCE OUTCOMES IN TYPE 2 DIABETES
ORTHO-ATI DELIVERS PROMISING RESULTS IN TREATING HIP TENDON PAIN
STEM CELL AGENCY INVESTS $32 MILLION TOWARD THERAPIES FOR SPINAL CORD INJURY AND HIV/AIDS
SANGAMO BIOSCIENCES ANNOUNCES PUBLICATION OF PRECLINICAL DATA DEMONSTRATING GENE CORRECTION IN SCID-X1 HUMAN HEMATOPOIETIC STEM CELLS
DEVICE PRODUCES PACKAGED BATCHES OF STEM CELLS FOR REGENERATIVE MEDICINE
BIORESTORATIVE THERAPIES SIGNS RESEARCH AGREEMENT WITH PFIZER INC.
ROSLIN CELLS ANNOUNCES NEW CELL THERAPY MANUFACTURING CONTRACT WITH PFIZER INC.

List Of Tables

I. REPORT FOCUS
1. REGENERATIVE MEDICINE THERAPEUTICS COMPANIES BREAKDOWN - %
2. REGENERATIVE MEDICINE CELL & TISSUE BANKS BREAKDOWN - %
3. TISSUE ENGINEERING PRODUCTS CURRENTLY AVAILABLE IN THE MARKET FOR FOLLOWING AREAS
4. ECONOMIC IMPACT OF VARIOUS DISEASES (IN $USD BILLION)
5. MARKETED CELL THERAPIES BY JURISDICTION FOR USA, EUROPE, SOUTH KOREA, JAPAN, ISRAEL, CANADA & NEW ZEALAND
6. LEADING COMMERCIAL CELL THERAPY PRODUCTS OF KEY COMPANIES
7. CELL THERAPY TRIALS BY THERAPEUTIC AREA FOR EARLY TO MID-STAGE (PHASE 1, 1/2, 2) - % BREAKDOWN
8. LIST OF THERAPEUTIC AREAS IDENTIFIED, VECTORS USED AND GENE TYPES TRANSFERRED IN GENE THERAPY CLINICAL TRIALS
9. USA ANNUAL HEALTHCARE COST PER CAPITA BY AGE (IN $USD)
10. HEALTHCARE EXPENSES IN 2009 BY EXPENSE CATEGORY (FROM HEALTH U.S.A, 2011)

II. REGENERATIVE MEDICINE - MARKET BRIEFING
THE AMERICAS
11. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR THE AMERICAS CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
12. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
13. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR EUROPE CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
14. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF EUROPEAN MARKET VALUE - (2016-2019)

ASIA-PACIFIC
15. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR ASIA-PACIFIC CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
16. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
17. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR REST OF WORLD CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
18. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF REST OF WORLD MARKET VALUE - (2016-2019)

II. MARKET ANALYSIS
19. GLOBAL REGENERATIVE MEDICINE - SEGMENTATION BY THERAPEUTIC AREAS

REGENERATIVE MEDICINE GLOBAL
20. REGENERATIVE MEDICINE MARKET - GLOBAL CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
21. REGENERATIVE MEDICINE - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
22. REGENERATIVE MEDICINE - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - BY GEOGRAPHY
THE AMERICAS
23. REGENERATIVE MEDICINE - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
24. REGENERATIVE MEDICINE - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
25. REGENERATIVE MEDICINE - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
26. REGENERATIVE MEDICINE - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC
27. REGENERATIVE MEDICINE - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
28. REGENERATIVE MEDICINE - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
29. REGENERATIVE MEDICINE - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
30. REGENERATIVE MEDICINE - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - BY THERAPEUTIC AREA
31. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR GLOBAL CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
32. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF GLOBAL MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - THERAPEUTIC AREA - BY GEOGRAPHY
ORTHOPEDICS
33. ORTHOPEDICS MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
34. ORTHOPEDICS - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS
35. ORTHOPEDICS MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
36. ORTHOPEDICS - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
37. ORTHOPEDICS MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
38. ORTHOPEDICS - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC
39. ORTHOPEDICS MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
40. ORTHOPEDICS - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
41. ORTHOPEDICS MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
42. ORTHOPEDICS - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

SKIN/INTEGUMENTARY
43. SKIN/INTEGUMENTARY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
44. SKIN/INTEGUMENTARY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS
45. SKIN/INTEGUMENTARY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
46. SKIN/INTEGUMENTARY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
47. SKIN/INTEGUMENTARY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
48. SKIN/INTEGUMENTARY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC
49. SKIN/INTEGUMENTARY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
50. SKIN/INTEGUMENTARY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
51. SKIN/INTEGUMENTARY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
52. SKIN/INTEGUMENTARY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

CARDIOLOGY
53. CARDIOLOGY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
54. CARDIOLOGY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS
55. CARDIOLOGY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
56. CARDIOLOGY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
57. CARDIOLOGY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
58. CARDIOLOGY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC
59. CARDIOLOGY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
60. CARDIOLOGY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
61. CARDIOLOGY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
62. CARDIOLOGY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

NEUROLOGY
63. NEUROLOGY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
64. NEUROLOGY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS
65. NEUROLOGY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
66. NEUROLOGY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
67. NEUROLOGY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
68. NEUROLOGY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC
69. NEUROLOGY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
70. NEUROLOGY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
71. NEUROLOGY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
72. NEUROLOGY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

UROLOGY
73. UROLOGY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
74. UROLOGY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS
75. UROLOGY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
76. UROLOGY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
77. UROLOGY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
78. UROLOGY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC
79. UROLOGY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
80. UROLOGY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
81. UROLOGY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
82. UROLOGY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE)
83. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
84. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS
85. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
86. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE
87. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
88. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC
89. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
90. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD
91. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
92. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES - BY TYPE
93. REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES MARKET - CELLS AND -BIOMATERIALS, BIOMOLECULES, MANUFACTURING FACTORS AND OTHER FOR GLOBAL CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
94. REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES - CELLS AND BIOMATERIALS, BIOMOLECULES, MANUFACTURING FACTORS AND OTHER - % OF GLOBAL MARKET VALUE - (2016-2019)

B. GROWTH RATE ANALYSIS
95. REGENERATIVE MEDICINE MARKET - GEOGRAPHIC REGION - % GROWTH RATE FORECASTS - (2013-2019)
96. REGENERATIVE MEDICINE - BY THERAPEUTIC AREA - % GROWTH RATE FORECASTS FOR ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - (2013-2019)

C. INVESTMENT FOCUS
97. REGENERATIVE MEDICINE - FORECASTED CAGR% - 2013-2019 - TOP 8 COUNTRIES - USA, BRAZIL, SPAIN, RUSSIA, CHINA, JAPAN, SOUTH KOREA AND INDIA
98. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - FORECASTED CAGR% - VALUE - 2012-2018 - TOP 8 COUNTRIES - USA, JAPAN, CHINA, FRANCE, INDIA, SOUTH KOREA, RUSSIA AND BRAZIL

III. INDUSTRY OVERVIEW
99. WORLDWIDE KEY PLAYERS INTO REGENERATIVE MEDICINE INDUSTRY THAT PROJECT IMPROVED MARKET ACTIVITIES IN THE NEAR FUTURE

California Institute for Regenerative Medicine Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

California Institute for Regenerative Medicine Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

United States Bone Substitute for Regenerative Dentistry Market Report 2016

Notes:Sales, means the sales volume of Bone Substitute for Regenerative DentistryRevenue, means the sales value of Bone Substitute for Regenerative DentistryThis report studies sales (consumption) of Bone Substitute for Regenerative

USD 3800View Report

Europe Regenerative Medicine Market Report 2016

Notes:Sales, means the sales volume of Regenerative MedicineRevenue, means the sales value of Regenerative MedicineThis report studies sales (consumption) of Regenerative Medicine in Europe market, especially in Germany, UK, France,

USD 3900View Report

California Institute for Regenerative Medicine Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

California Institute for Regenerative Medicine Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

Europe Regenerative Medicine Market Report 2016

Notes:Sales, means the sales volume of Regenerative MedicineRevenue, means the sales value of Regenerative MedicineThis report studies sales (consumption) of Regenerative Medicine in Europe market, especially in Germany, UK, France,

USD 3900View Report

United States Regenerative Medicine Market Report 2016

Notes:Sales, means the sales volume of Regenerative MedicineRevenue, means the sales value of Regenerative MedicineThis report studies sales (consumption) of Regenerative Medicine in United States market, focuses on the top

USD 3800View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 4710
  • Enterprise Wide Licence    $ 6510
$ 4710

Reports Details

Published Date : Apr 2015
No. of Pages :379
Country :Global
Category :Healthcare
Publisher :Axis Research Mind
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment